



Remibrutinib demonstrated continuous efficacy and favorable safety in patients with chronic spontaneous urticaria in the randomized withdrawal period of the phase 3b REMIXED extension study

M. Metz, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Mosnaim, V. Jain, K. Hayama, U. Lippert, M. Palumbo, B. Yang, K. Kulthanan, Y.M. Ye, S. Dahale, S. Haemmerle, L. Jaskiewicz, K. Lheritier, C. Field, L. Wei, S. Saini

Please use this [LINK](#) to access the abstract after June 8, 2026, once it is available on the congress website